Navigation Links
U.S. Navy Requested Operations Trial on FDA Hold
Date:12/30/2008

CAMBRIDGE, Mass., Dec. 30 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the Food and Drug Administration has advised the U.S. Naval Medical Research Center ("NMRC") by letter that it may not initiate a clinical trial of Biopure's product Hemopure [hemoglobin glutamer - 250 (bovine)], under a proposed protocol submitted to the FDA on November 21, 2008. As previously announced, the Navy had filed a protocol for a proposed trial for the resuscitation of operational casualties with severe hemorrhagic shock without availability of blood transfusions ("Op RESUS").

While the FDA letter acknowledges that the proposed trial addresses some of FDA's concerns previously communicated, it gives three regulatory bases for the hold: safety of subjects, protocol design deficient to meet its stated objectives; and the content of the investigator brochure (a summary of information for those carrying out the trial) and related items. Concerning safety, the FDA hold letter refers to the risk of exacerbation of bleeding resulting from product infusion and the "adverse event profile of [Hemopure]." However, the letter refers in particular to the results of three previous trauma trials with adverse mortality rates, none of which was a Hemopure trial and one of which, according to the FDA, did not involve a hemoglobin based oxygen carrier. According to the FDA, based on these trials with other products, it cannot presently approve IND protocols with agents that may raise blood pressure in acute hemorrhagic shock.

The letter requests a "Clinical Hold Complete Response." The Company does not know how the NMRC will proceed.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. On November 21, 2008, the Company announced that it had terminated most of its work force for financial reasons. Using its limited resources, the Company is developing Hemopure and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold more than 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that the Company or the U.S. Navy will be able to proceed with any clinical trial of Hemopure. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, delays and adverse determinations by the FDA and other regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on September 15, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

    Contact:  Rob Skiba
              Biopure Corporation
              (617) 234-6500
              IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. $3 Million Requested by UNFPA to Help Women and Girls Displaced by Myanmar Cyclone
2. Danialle Karmanos Work It Out Names Tracey Secco as Director of Operations
3. PRA International Expands Operations in Mexico
4. DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations
5. Duane Reade Holdings, Inc. Further Strengthens Management Team With Addition of Frank Scorpiniti, SVP, Pharmacy Operations
6. Operations engineering for more efficient operating rooms
7. Frost & Sullivan Lauds StatCom for Its Hospital Operations System
8. Warriors Unite: Mike Ditka & the Gridiron Greats Form Partnership to Assist Retired NFL Players & U.S. Military Special Operations Personnel
9. Jonathan Jacobson Appointed General Manager, Global Business Strategies & Operations, Menicon Co., Ltd.
10. AmeriCares Launches India Operations
11. Accumetrics, Inc. Appoints William Dippel as Executive Vice President of Operations and R&D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
(Date:6/24/2016)... Research and Markets has ... 2015-2025: Applications, Technologies, Forecasts" report to their ... Electronics, Smart Skin, Structural Health Monitoring, Composite Smart ... electronics involves electronic and/or electrical components and circuits ... structures such as vehicle bodies or conformally placed ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: